Open-label Pharmakokinetic Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Injection or 1000 mg Intravenous Infusion to Patients With Inflammatory Bowel Disease (PK-IBD-02)

Trial Profile

Open-label Pharmakokinetic Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Injection or 1000 mg Intravenous Infusion to Patients With Inflammatory Bowel Disease (PK-IBD-02)

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2015

At a glance

  • Drugs Iron isomaltoside 1000 (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Pharmacokinetics
  • Sponsors Pharmacosmos
  • Most Recent Events

    • 15 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top